IGHID 12219 - A Brief Alcohol Intervention for PrEP Use Among MSM in Vietnam: A Randomized Controlled Trial (BPrEP)

Sponsor
University of North Carolina, Chapel Hill (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06094634
Collaborator
National Institute on Alcohol Abuse and Alcoholism (NIAAA) (NIH), National Institutes of Health (NIH) (NIH), Hanoi Medical University (Other), Ohio State University (Other), Johns Hopkins University (Other), University of Washington (Other)
564
1
2
42
13.4

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the effectiveness of a brief alcohol intervention (BAI) vs. standard of care (SOC) to improve pre-exposure prophylaxis (PrEP) use among men who have sex with men (MSM) with unhealthy alcohol use initiating or re-initiating PrEP in Vietnam.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: The Brief Alcohol Intervention (BAI): Behavioral
N/A

Detailed Description

This is a two-arm effectiveness randomized controlled trial (RCT) to compare the brief alcohol intervention (BAI) to the standard of care (SOC) among MSM with unhealthy alcohol use who are initiating or reinitiating oral, event-driven, or injectable PrEP in Vietnam.

The BAI draws from Motivational Interviewing (MI)/Motivational Enhancement Therapy (MET) and Cognitive Behavioral Therapy (CBT) and includes 2 in-person sessions and 2 telephone sessions.

Eligible participants (n=564) will be randomized 1:1 to each arm (282 per arm). Additional assessments among a subset of participants in the BAI arm will assess acceptability of the intervention (n=48) Study activities will span 5 years. Individual MSM participants will be followed-up for 12 months with assessment visits at 3, 6, 9, and 12 months after enrollment.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
564 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
IGHID 12219 - A Brief Alcohol Reduction Intervention to Reduce Alcohol Use and Improve PrEP Outcomes Among Men Who Have Sex With Men: A Randomized Controlled Trial in Vietnam
Anticipated Study Start Date :
Jan 1, 2024
Anticipated Primary Completion Date :
Jul 1, 2027
Anticipated Study Completion Date :
Jul 1, 2027

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Assessment-only control

Participants receive study assessment visits and standard of care from providers at the PrEP clinic.

Experimental: The Brief Alcohol Intervention (BAI)

Participants receive the Brief Alcohol Intervention (2 in-person sessions and 2 phone sessions), study assessment visits, and standard of care from providers at the PrEP clinic.

Behavioral: The Brief Alcohol Intervention (BAI): Behavioral
The BAI draws from Motivational Interviewing (MI)/Motivational Enhancement Therapy (MET) and Cognitive Behavioral Therapy (CBT) and comprises 2 in-person face-to-face sessions and 2 booster telephone sessions by a trained counselor.

Outcome Measures

Primary Outcome Measures

  1. PrEP Persistence [12 months]

    PrEP persistence is a measure of ongoing PrEP usage, defined as consistent presentation for care and refills.

  2. Binge Drinking [12 months]

    The number of days with ≥5 standard drinks of alcohol per occasion among the previous 30 days as assessed on the Timeline Followback.

  3. Incremental Cost-Effectiveness Ratio (ICER) [12 months]

    The incremental cost-effectiveness ratio (ICER) is expressed as the incremental cost of the Brief Alcohol Intervention (BAI) per quality adjusted life-year (QALY) gained. ICER is defined as [Ci - Ca]/[Ei - Ea] with Ci and Ca being the respective costs of the BAI [i] and assessment only [a], and Ei and Ea the corresponding effectiveness.

  4. Acceptability of the brief alcohol intervention, as measured with mHIST [3 months]

    Acceptability is an implementation-focused outcome and will be assessed using the Mental Health Implementation Science Tools (mhIST) Acceptability Scale for consumers, which consists of 15 items containing responses on a 4-point Likert scale. The mhIST score is calculated as the mean score of all responses ranging from 1-4. Higher mhIST scores indicate higher acceptability.

  5. Feasibility - proportion completed 4 sessions (intervention arm) [7 weeks]

    Feasibility is an implementation-focused outcome and will be measured as the BAI completion rate among MSM. Three metrics will be considered, measured from the date of the first in-person session. The first metric will be the proportion of participants who completed all 4 sessions among those who were assigned to the intervention arm.

  6. Feasibility - proportion completed 2 sessions (intervention arm) [7 weeks]

    Feasibility is an implementation-focused outcome and will be measured as the BAI completion rate among MSM. Three metrics will be considered, measured from the date of the first in-person session. The second metric will be the proportion of participants who completed at least 2 sessions among those who were assigned to the intervention arm.

  7. Feasibility - proportion completed 4 sessions (among initiators) [7 weeks]

    Feasibility is an implementation-focused outcome and will be measured as the BAI completion rate among MSM. Three metrics will be considered, measured from the date of the first in-person session. The third metric will be the proportion of participants who completed at least 4 sessions among those who initiated at least one session.

Secondary Outcome Measures

  1. PrEP Adherence [Up to 12 months]

    PrEP adherence is a measure of pill-taking behavior and will be assessed by self-report and pharmacy records. Adherence will be assessed per person based on the type of PrEP prescribed but will be compared as a single measure. Oral and event-driven PrEP adherence will be assessed as self-reported number of doses taken. Oral PrEP adherence is defined with two thresholds: ≥ 4 days/week, a threshold consistent with HIV prevention among MSM, and 7 days, indicating perfect adherence. Event-driven PrEP adherence will be defined as completion of the 2+1+1 regimen for every reported condomless anal intercourse event.

  2. Risk-aligned PrEP use [Up to 12 months]

    Risk-aligned PrEP use is a measure of whether PrEP use is consistent with concurrent risk behavior. It is defined as persistent oral/injectable PrEP, event-driven PrEP (2+1+1) with adherence, or clinician-supervised PrEP discontinuation for reduced sexual risk More specifically, risk-aligned PrEP is defined as: persistent oral or injectable PrEP, event-driven PrEP (2+1+1) with 100% adherence, or appropriate PrEP discontinuation for reduced sexual risk, using 1 of 2 definitions: clinician-approved PrEP discontinuation for reduced sexual risk, or PrEP self-discontinuation with documented minimal risk by Vietnamese guidelines and no concurrent sexually transmitted infection (STI).

  3. Number of Drinking Days [Up to 12 months]

    Number of drinking days is defined as the number of days with any alcohol use, among the previous 30 days as assessed on the Timeline Followback. The timeline followback will be administered at enrollment, 3 months, 6 months, 9 months, and 12 months.

  4. Number of Drinks Per Drinking Day [Up to 12 months]

    Drinks per drinking day is defined as the number of standard drinks of alcohol consumed on a drinking day, among the past 30 days as assessed on the Timeline Followback. The timeline followback will be administered at enrollment, 3 months, 6 months, 9 months, and 12 months.

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Newly initiating PrEP or re-initiating PrEP after at least 3 months from a missed PrEP appointment, based on Vietnamese PrEP guidelines

  • Assigned male sex at birth

  • Identify as male

  • Receptive or penetrative anal intercourse with a man in the past 6 months

  • AUDIT-C score ≥ 4 (unhealthy alcohol use)

  • 16 years of age or older

  • Intention to receive PrEP care in Hanoi for 12 months

  • Willingness to provide informed consent

Exclusion Criteria:
  • Psychological disturbance, cognitive impairment, or threatening behavior

  • Unwilling to provide locator information

  • Current participation in alcohol programs

  • Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA) ≥ 10, indicating risk for alcohol withdrawal

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hanoi Medical University Hanoi Vietnam

Sponsors and Collaborators

  • University of North Carolina, Chapel Hill
  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  • National Institutes of Health (NIH)
  • Hanoi Medical University
  • Ohio State University
  • Johns Hopkins University
  • University of Washington

Investigators

  • Principal Investigator: Vivian F Go, MD, University of North Carolina
  • Principal Investigator: William C Miller, MD, Ohio State University
  • Principal Investigator: Le Minh Giang, PhD, Hanoi Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
NCT06094634
Other Study ID Numbers:
  • 23-0256
  • R01AA030479
First Posted:
Oct 23, 2023
Last Update Posted:
Oct 23, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of North Carolina, Chapel Hill
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 23, 2023